Biophage Pharma Announces Important Contribution of Canadian Government to Open the Brazilian Market.MONTREAL -- The Canadian International Development Agency The Canadian International Development Agency (CIDA) is a Canadian government agency which administers foreign aid programs in developing countries. CIDA operates in partnership with other Canadian organizations in the public and private sectors as well as other (CIDA CIDA Canadian International Development Agency CIDA Council for Interior Design Accreditation (Grand Rapids, MI) CIDA Centro de Información Documental de Archivos CiDA Certificate in Digital Applications ) to Provide Assistance to Biophage Biophage Pharma Inc. (TSX TSX Toronto Stock Exchange (TSE before April, 2002) TSX Transfer from Stack Pointer to Index TSX True Space Extension VENTURE:BUG), a biopharmaceutical company engaged in the development of new therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. and clinical diagnostics based on its leading expertise in immunology immunology, branch of medicine that studies the response of organisms to foreign substances, e.g., viruses, bacteria, and bacterial toxins (see immunity). Immunologists study the tissues and organs of the immune system (bone marrow, spleen, tonsils, thymus, lymphatic and phage therapy Phage therapy is the therapeutic use of lytic bacteriophages to treat pathogenic bacterial infections. Bacteriophages, or "phages" are viruses that invade only bacterial cells and, in the case of lytic , today announced that it has received an important contribution from the Canadian Government through the Canadian International Development Agency (CIDA) to open the Brazilian market to Biophage's therapeutic and diagnostic products. "We are very pleased to accept this financial support from CIDA, which allow us to offer our technologies to the world. This support will help Biophage in its effort to find a long-term collaborator in Brazil, who can enhance our expertise and know-how and provide access to other Latin American markets," stated Dr. Rosemonde Mandeville, President and Chief Executive Officer of Biophage Pharma Inc. "Brazil needs help and support to deliver improved water supplies to its population. Both our Phage Therapy and Nanosensor technologies can be part of the solution as its application to water management could help in reducing the incidence of water-borne diseases Water-borne disease Disease acquired by drinking water contaminated at its source or in the distribution system, or by direct contact with environmental and recreational waters. and to help clean up the local beaches by restoring and protecting the environmentally deteriorated rivers and coastal areas nearby," concluded Dr Mandeville. About Biophage Pharma Inc. Biophage Pharma Inc. is a Canadian biopharmaceutical company developing new therapeutic and diagnostic products using phage-based technology. Founded in 1995, Biophage is located at the Biotechnology Research Institute in Montreal and employs 15 people, including a team of 13 researchers. Through an active research and development program, as well as in-licensing and collaboration agreements, Biophage is building a portfolio of promising new therapeutics collaboration agreements, Biophage is building a portfolio of promising new therapeutics (www.biophage.com). Biophage Pharma Inc. (TSX VENTURE:BUG) |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion